help button home button Am J Pathol International Conference on Pathology of Chest Diseases
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Joensuu, H.
Right arrow Articles by Klemi, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Joensuu, H.
Right arrow Articles by Klemi, P. J.

American Journal of Pathology, Vol 132, 145-151, Copyright © 1988 by American Society for Investigative Pathology

REGULAR ARTICLES

DNA aneuploidy in adenomas of endocrine organs

H Joensuu and PJ Klemi
Department of Radiotherapy, University Central Hospital of Turku, Finland.

The nuclear DNA content of 44 pituitary, 49 thyroid, 54 parathyroid, and 17 adrenal adenomas was analyzed from paraffin-embedded tissue with flow cytometry. Interpretable histograms of good quality (CV less than 7%, mean CV, 4%) were obtained in 96% of the cases. Unequivocal evidence of DNA aneuploidy was found in 29% of pituitary, 25% of thyroid, 35% of parathyroid, and in 53% of adrenal adenomas. Excluding the multiploid (N = 2) and tetraploid adenomas (N = 5), the DNA indices of aneuploid adenomas were generally small (mean, 1.34). Patients with a diploid thyroid or parathyroid adenoma had a lower mean age at diagnosis than patients with a nondiploid adenoma. None of the adenomas gave rise to metastases after conservative surgery. It is concluded that DNA aneuploidy is common in endocrine adenomas and that the presence of DNA aneuploidy is not incompatible with a benign histologic diagnosis. The usefulness of DNA aneuploidy as a conclusive sign of malignancy in clinical practice is questioned.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
A. L. Stratford, K. Boelaert, L. A. Tannahill, D. S. Kim, A. Warfield, M. C. Eggo, N. J. L. Gittoes, L. S. Young, J. A. Franklyn, and C. J. McCabe
Pituitary Tumor Transforming Gene Binding Factor: A Novel Transforming Gene in Thyroid Tumorigenesis
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4341 - 4349.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
T. Isaka, A. L. Nestor, T. Takada, and D. C. Allison
Chromosomal Variations Within Aneuploid Cancer Lines
J. Histochem. Cytochem., October 1, 2003; 51(10): 1343 - 1353.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
E. Kebebew, C. Arici, Q.-Y. Duh, and O. H. Clark
Localization and Reoperation Results for Persistent and Recurrent Parathyroid Carcinoma
Arch Surg, August 1, 2001; 136(8): 878 - 885.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. Hemmer, V.-M. Wasenius, C. Haglund, Y. Zhu, S. Knuutila, K. Franssila, and H. Joensuu
Deletion of 11q23 and Cyclin D1 Overexpression Are Frequent Aberrations in Parathyroid Adenomas
Am. J. Pathol., April 1, 2001; 158(4): 1355 - 1362.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Brown and C. Wittwer
Flow Cytometry: Principles and Clinical Applications in Hematology
Clin. Chem., August 1, 2000; 46(8): 1221 - 1229.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. M. Parfitt, Q. Wang, and S. Palnitkar
Rates of Cell Proliferation in Adenomatous, Suppressed, and Normal Parathyroid Tissue: Implications for Pathogenesis
J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 863 - 869.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by the American Society for Investigative Pathology.